Allergan plc said it will buy Lifecell Corp., a company that makes regenerative medicine products for tissue reinforcement, from privately held Acelity LP for $2.9 billion in cash, a purchase partly driven by growing demand for reconstructive breast surgeries among women with breast cancer. About one in eight U.S. women will develop invasive breast cancer over the course of their lifetime, and, globally, breast cancer now represents one in four of all cancers in women, the company said, citing statistics from the nonprofit Breastcancer.org. The acquisition will add a portfolio of dermal matrix products used...
Allergan plc said it will buy Lifecell Corp., a company that makes regenerative medicine products for tissue reinforcement, from privately held Acelity LP for $2.9 billion in cash, a purchase partly driven by growing demand for reconstructive breast surgeries among women with breast cancer.
Allergan plc said it will buy Lifecell Corp., a company that makes regenerative medicine products for tissue reinforcement, from privately held Acelity LP for $2.9 billion in cash, a purchase partly driven by growing demand for reconstructive breast surgeries among women with breast cancer.
Just months after a phase III trial miss for TNX-102 SL in fibromyalgia elevated post-traumatic stress disorder (PTSD) to the lead indication for the Tonix Pharmaceuticals Holding Corp. drug, it has secured FDA breakthrough status in the condition, which is often tied to military combat trauma.
Vtv Therapeutics Inc. reported that its oral GLP-1 receptor agonist, TTP273, helped type 2 diabetics on stable doses of metformin achieve mean placebo-subtracted HbA1c differences of up to -0.86 percent during a phase II study, giving it confidence to continue advancing the program, one of two diabetes-focused efforts at the company.
Third Rock Ventures LLC has invested $55 million in a series A financing of Goldfinch Bio, a new Cambridge, Mass.-based company founded to discover and develop precision kidney disease therapies for conditions including focal segmental glomerulosclerosis (FSGS) and polycystic kidney disease. Using a patient registry to collect and integrate genomic and phenotypic data, it will focus on helping molecularly defined patient groups.
Partners Bayer AG and Versant Ventures have committed $225 million in series A financing to launch Bluerock Therapeutics, a regenerative medicine company focused on developing induced pluripotent stem cell therapies for diseases with significant cell loss and diminished self-repair potential.
Emergent Biosolutions Inc. has lined up federal support for follow-on purchases of up to $1.1 billion of its anthrax vaccines that will keep the strategic national stockpile fresh as the government prepares for an anticipated 2019 transition.
TCR2 Therapeutics Inc., a Cambridge, Mass.-based immunotherapy developer targeting solid tumors with an approach to T-cell therapies that its execs say will improve safety and durability, has landed a $44.5 million series A financing expected to carry its anticancer aspirations into the clinic by the end of 2018.
Top-line data from a trial of HS-410 (vesigenurtacel-L), Heat Biologics Inc.'s experimental non-muscle invasive bladder cancer (NMIBC) vaccine, fell short of hitting its primary endpoint in a phase II study, robbing the Durham, N.C.-based company of a desired chance to seek an accelerate approval in phase III, but not of its hope for success, CEO and founder Jeff Wolf told BioWorld Today.
